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Abstract objective Kenya, like many resource-constrained countries, has a single mycobacterial laboratory,
centrally located in Nairobi, with capacity for drug-susceptibility testing (DST) – the gold standard in
diagnosing drug-resistant tuberculosis. We describe and evaluate a novel operational design that
attempts to overcome diagnostic delivery barriers.
methods Review of the public DST programme identiﬁed several barriers limiting access: lack of
programme awareness amongst physicians, limited supplies, unreliable transport and no specimen
tracking methods. Staff visited 19 clinic sites in western Kenya and trained healthcare providers in regard
to the novel diagnostics model. Provincial laboratory registries were reviewed to assess utilization of
DST services prior to and after programme modiﬁcation.
results Onsite training consisted of the inclusion criteria for re-treatment patients – the high-priority
group for DST. Additionally, infrastructural support established a stable supply chain. An existing
transport system was adapted to deliver sputum specimens. Task shifting created an accession and
tracking system of specimens. During the 24 months post-implementation, the number of re-treatment
specimens from the catchment area increased from 9.1 to 23.5 specimens per month. In comparing
annual data pre- and post-implementation, the proportion of re-treatment cases receiving DST increased
from 24.7% (n = 403) to 32.5% (n = 574) (P < 0.001), and the number of multidrug-resistant (MDR)
TB cases increased from 5 to 10 cases.
conclusion The delivery model signiﬁcantly increased the proportion of re-treatment cases receiving
DST. Barriers to accessing the national MDR-TB surveillance programme can be overcome through an
operational model based on pragmatic use of existing services from multiple partners.
keywords tuberculosis, multidrug-resistant, microbial sensitivity tests, Kenya, delivery of health care
Introduction
A previous history of tuberculosis (TB) treatment has been
identiﬁed in a number of epidemiologic studies as a
risk factor for drug-resistant tuberculosis and multidrug-
resistant TB (MDR-TB) (Espinal et al. 2001; Faustini et al.
2006). The need for ‘re-treatment’ may reﬂect undiagnosed
primary drug-resistant TB, poor adherence or defaulting,
leading to acquired resistance, short-term relapse of TB or
re-infection. Therefore, re-treatment patients are a high-
priority group for whom culture and drug-susceptibility
testing (DST), the gold standard for diagnosing MDR-TB,
should be performed.
According to a 2010 WHO report, only 18% of re-
treatment tuberculosis cases in Kenya received DST despite
national guidelines and programmatic support for this
practice (World Health Organization 2010b). Kenya
currently has only one laboratory, the Central Reference
Laboratory (CRL) in Nairobi, with DST capacity. The
current national TB re-treatment surveillance programme
as established by the Division of Leprosy, TB, and Lung
Disease (DLTLD) employs countrywide specimen trans-
port routing systems. The DLTLD contracts a private
courier company to ship all sputum specimens of ‘target
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ﬁnancial cost to the patient. TB clinic staff at the local level
identiﬁes these patients, collects sputa and delivers speci-
mens to the courier company’s drop point. Samples are
transported to the CRL on at least a weekly basis. Paper
results are returned to the clinics in the same manner.
This centralized approach has been used in other
settings with limited laboratory services but frequently
leads to delays in turnaround time up to 5 months
(Yagui et al. 2006; Shin et al. 2008; Singla et al. 2009).
During this delay, patients with drug-resistant TB may
continue failing empirical regimens, leading to commu-
nity transmission and resistance ampliﬁcation (Farmer
et al. 1998; Furin et al. 2000). Although successful
treatment of MDR-TB has been demonstrated in
resource-poor settings (Mitnick et al. 2003; Van Deun
et al. 2010), studies have shown mortality rates of
patients awaiting DST results and ultimately diagnosed
with MDR-TB to range from 12 to 50% (Singla et al.
2009). Harries et al. (2004) published a report from
Malawi showing that despite implementation of a new
bus transport system for re-treatment specimens, 60% of
cases resulted in a sample not being received by the
central laboratory. Beyond transportation, a variety of
other operational challenges related to rural clinics leads
to delay, including frequent staff turnover with inade-
quate training regarding the re-treatment programme and
stock-outs of sputum collection bottles and laboratory
forms (Harries et al. 2004; Shin et al. 2008; Grifﬁn et al.
2009; Singla et al. 2009). Clinical staff is generally not
trained to set up accession and tracking systems in the
same manner that laboratories are; many clinics have no
record of which patient had a specimen collected or
when the specimen was sent to the laboratory. Logistical
dilemmas in the operational mechanism may result in up
to 29% of conﬁrmed MDR-TB cases having ‘lost’ results
(Grifﬁn et al. 2009). Consequently, screening of high-risk
patients is not completed, and health system-based
problems cannot be identiﬁed because of the lack of
documentation.
Decentralization of MDR-TB surveillance services
may occur through the addition of regional laboratory
centres with DST capacity. However, such an approach is
too costly for many of the high-burden TB countries.
The recent development of Xpert
  Mycobacterium
tuberculosis⁄rifampicin and other cartridge-based, rapid
diagnostic systems will be useful for point of care diagnosis
of TB and drug-resistant TB; however, these diagnostic
tools do not eliminate the need to continue to invest in
culture and DST capacity (World Health Organization
2011). DST decentralization or implementation of rapid
testing methods will only minimally impact patient
outcomes if the pre- and post-DST logistical barriers are
not addressed (Shin et al. 2008).
Here, we describe a healthcare delivery model that
increases accessibility to DST services in western Kenya by
addressing operational barriers. This modiﬁcation of the
national TB re-treatment surveillance programme focuses
on establishing partnerships to collaboratively build upon
existing infrastructure.
Methods
Moi University School of Medicine (MUSOM) and Moi
Teaching and Referral Hospital (MTRH) are located in
Eldoret, 300 km west of Nairobi. MTRH is one of two
established referral hospitals in Kenya, supplying both
local primary care and secondary referral care (North
Rift Valley and Western Provinces). In 2000, MUSOM
and MTRH, with their U.S. partners, established AM-
PATH, originally titled Academic Model for Prevention
and Treatment of HIV⁄AIDS and now the Academic
Model Providing Access to Healthcare (AMPATH).
Academic Model Providing Access to Healthcare consists
of 23 HIV care clinics incorporated into the Ministry of
Health units with a centralized AMPATH Reference
Laboratory (ARL) and a transport system for personnel
and laboratory specimens. The ARL includes the
Mycobacteriology Reference Laboratory (MRL), estab-
lished under a Foundation for Innovative New Diag-
nostics (FIND) grant. The MRL is capable of smear,
liquid and solid culture, and DST; however, funding to
support routine culture and DST has not yet been
established.
The CRL routinely requires 12 weeks or more for
completing DST because of a multistep process that
includes use of solid media. Isolation of mycobacteria on
solid media can take up to 8 weeks. Thereafter, DST is
performed with Mycobacteria Growth Indicator Tube
(MGIT), which involves a liquid medium.
In October 2007, MRL staff visited 19 health facilities
collaborating with the AMPATH programme. With the
support of the DLTLD, MRL staff provided training to all
physicians, nurses and laboratory technicians of the public
chest and HIV clinics as well as district Ministry of Health
coordinators regarding the inclusion criteria for ‘re-treat-
ment cases’ and their signiﬁcance. Training also focused on
accessing the AMPATH transport and laboratory support
systems to facilitate transporting of specimens, stocking of
sputum collection bottles and tracking of laboratory results.
A pre- and post-programme retrospective evaluation was
performed. All re-treatment cases documented by the MRL
and CRL were included in the study. Amongst the
documented re-treatment cases, no cases were excluded.
Tropical Medicine and International Health volume 17 no 3 pp 374–379 march 2012
P. H. Park et al. Increasing access to the MDR-TB surveillance programme
ª 2011 Blackwell Publishing Ltd 375MRL tracking database was reviewed to assess utilization
of the services and results turnaround times. The national
CRL registry provided provincial-level data on the pro-
portion of re-treatment cases receiving DST and MDR-TB
diagnosis. Fisher’s exact test was used to assess for
statistical signiﬁcance.
Results
Diagnostics delivery model
Upon completion of on-site training at 19 satellite health
facilities, a novel logistical model was in place for accessing
the national MDR-TB surveillance programme (Figure 1).
TB care providers send all re-treatment specimens to the
MRL via AMPATH vehicles. AMPATH vehicles routinely
visit these health facilities 1–4 times per week, carrying
supplies, specimens and personnel. TB care providers were
asked to schedule sputum collection of re-treatment cases
on or immediately prior to the day of transport delivery
whenever possible. For those specimens requiring storage,
sputum-containing bottles were stored in a designated site
devoid of sunlight and excess heat. Upon arrival to the
MRL, laboratory technicians accession specimens and
electronically document all relevant details: patient iden-
tiﬁcation, health facility, ordering physician, date of
specimen arrival, date of shipment to CRL, date of results
arrival and culture⁄DST results.
Specimen 
Collection @ Clinic 
w/possible storage
Specimens accessioned and 
details of each specimen 
entered into database
Culture and DST
Results transported 
to clinic
MRL calls CRL regarding  
results, then informs 
clinician by mobile phone
DST/Culture Specimen Collection and Results Tracking Algorithm
Vehicle transport to CRL – Nairobi  
Vehicle transport to MRL - Eldoret 
If > 12 weeks
1–6 days
7–9 weeks
1–7 days
1–7 days
Total estimated turnaround time:< 12 weeks
Results returned to 
MRL for database 
entry
Figure 1 Algorithm for DST⁄culture specimen collection, accession and electronic results tracking as implemented at 19 clinics in
the catchment area of the MRL in western, Kenya.
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appropriately stamped by MRL staff, so the CRL can
provide results to the treatment clinics via the MRL. Upon
receipt of results from the CRL, the MRL staff logs the
results in the electronic database. Paper laboratory results
are then returned to the ordering clinic via AMPATH
vehicles. MRL staff additionally report any drug resistance
to the requesting clinician by mobile phone.
The electronic database allows for establishment of a
steady supply chain in addition to the re-tracking policy
(Figure 1). Quarterly, MRL staff review the number of
specimens received per site and deliver an equivalent
number of culture bottles, specimen bags and request forms
to the clinic. An inventory of all specimen collection
supplies was documented during the initial site visits, and
MRL staff provided an additional surplus on that day as
needed. The re-tracking policy is an algorithm for identi-
fying delayed or potentially lost results. Specimen tracking
in the electronic database is performed bimonthly. Per
protocol, if the MRL does not receive a specimen report
from the CRL within 12 weeks, MRL staff contacts the
CRL by mobile phone to ascertain the status of the
specimen. Results are then either identiﬁed, pending,
deemed as inadequate sample (cracked bottle or
contaminant) or ‘lost’.
Post-implementation quantitative outcomes
During the 24-month period after the re-treatment sur-
veillance programme was instituted, the MRL facilitated
an average of 23.5 specimens per month from the catch-
ment area, vs. 9.1 specimens per month before the
programme started (Table 1). The proportion of re-
treatment cases from the catchment area receiving DST
annually increased from 24.7% (n = 403) to 32.5%
(n = 574) between 2006 and 2008 (P < 0.001). The num-
ber of MDR-TB cases identiﬁed in North Rift Valley and
Western Provinces also increased from ﬁve cases in 2006 to
10 cases in 2008. The number of participating satellite
clinics rose to >25 after the district DLTLD staff elected to
expand the programme to additional sites. Sputum samples
from neighbouring satellite clinics are now dropped off at
AMPATH-connected sites on the day of sputum transport.
The re-tracking policy was used for 33% (n = 206) of
the specimens, and 63% (n = 130) of re-tracked specimens
were successfully recovered to produce a documented
result. Therefore, 12% (n = 76) of all re-treatment cases at
the MRL were deemed as ‘lost’. The average turnaround
time for specimen results was 11.7 weeks including those
that required the re-tracking policy; average turnaround
time for specimens not requiring the re-tracking policy was
9.6 weeks.
Discussion
The modiﬁed TB retreatment surveillance programme at
AMPATH MRL resulted in a larger proportion of re-
treatment patients accessing DST service within the
catchment area. The programme operated through collab-
orations with various stakeholders that resulted in a series
of pragmatic operational interventions: education of staff
regarding the programme guidelines, establishment of
supply chain for laboratory forms and bottles, utilization
of an existing transport system and a dedicated tracking
system for results.
While baseline data are not available for turnaround
time, the MRL achieved its target goal of <12 weeks. We
also note that more than half of the delayed specimens
that would potentially be considered ‘lost’ were identiﬁed
to produce a reportable result. The need to use the re-
tracking policy for nearly one-third of all samples is a
reﬂection of the reality of the situation – limited organi-
zational infrastructure and inconsistent work ﬂow. This
points to the need for a standardized accession and
tracking system which the previous clinic-based system
did not have.
Table 1 Pre- and post-programme values
in relation to implementation of decentral-
ization model that occurred in the 4th
quarter of 2007
Pre-implementation Post-implementation
No. specimens collected
at MRL
9.1 23.5
No. re-treatment cases
in catchment area
1629 1765
% Re-treatment cases completing
DST in catchment area
24.7 32.5*
No. of MDR-TB cases identiﬁed
in catchment area
51 0
Turnaround time (weeks) of
MRL-accessioned specimens
N⁄A 11.7
*P < 0.001.
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local clinics as reﬂected by the DLTLD’s decision to
expand the programmatic structure to include more rural
sites. Based on informal interviews with local healthcare
providers, the acceptance of the programme has been due
to the increased reliability of return of results, improved
turnaround time, frequency of deliveries, stable supply
chain and more proximal drop points for specimen
delivery.
Two major challenges to both the uptake and sustain-
ability of the re-treatment surveillance programme are
maintenance of medical staff knowledge and maintenance
of the culture bottles supply chain. MRL staff revisited
three sites where participation rates were low. These site
visits consistently demonstrated high staff turnover with
new staff having limited knowledge of the programme
protocols. The lack of adherence by clinicians to
re-treatment protocols can have a devastating impact on
the ability to identify MDR-TB cases in the community. In
one study from Peru, perfect adherence by clinical staff to
national re-treatment guidelines would have resulted in a
50-fold increase in DST requests (Grifﬁn et al. 2009).
Regarding the supply chain, intermittent national shortages
of culture bottles inhibited the MRL from dispensing
supplies in a timely manner. Presently, a monthly re-
treatment surveillance report is reviewed by the central
team to target sites where re-education or examination of
supply chain issues is warranted. Formal agreements
between laboratories regarding prompt delivery schedules
of supplies are needed. Lastly, utilization of internet-based
medical records would also facilitate results tracking and
reduce turnaround time (Shin et al. 2008).
Limitations of the study include the inability to
identify the independent impact of each element of the
delivery model (training, supply chain, transport and re-
tracking). A pre- and post-test of all healthcare personnel
involved in a training session would be of value. In
addition, further operational research comparing inter-
vention clinics to non-intervention clinics with baseline
data would provide stronger controls accounting for
potential confounding variables, including geographic
temporal trends. Lastly, even after implementation of
this protocol, there still remains much room for
improvement regarding diagnostic delays and reliability
of results.
We were unable to calculate the cost of task shifting by
laboratory staff and transportation. However, we should
note that no new job positions or transportation routes
were created for the implementation of this modiﬁed
national re-treatment programme. The only new items
were the laboratory cell phone and cell phone airtime.
The major lessons of our programme are twofold:
(i) identiﬁcation of existing health system resources – the
expertise of the regional laboratory staff in training and
access, the AMPATH transport system and the DLTLD’s
supply chain with the MRL’s inventory monitoring –
which can be co-opted to assist national- or provincial-
level programmes; (ii) the establishment of a tracking
system that allows for programme monitoring and eval-
uation. According to a 2006 WHO report, only 9% of re-
treatment tuberculosis cases received DST in the WHO
African region with a goal of 90% by 2015 (World
Health Organization 2006, 2010a, 2010b). This prag-
matic approach to examine coexisting complementary
programmes and to establish monitoring systems may be
a feasible and immediate approach to increasing this
ﬁgure.
Harries et al. (2004) concluded that while the new
transport system alone was seen as partially beneﬁcial,
there exists a need for further operational research into the
details of systematically collecting and transporting spec-
imens without becoming ‘lost’. The advent of novel
diagnostics such as Xpert  (Boehme et al. 2010) has also
acknowledged the inevitable barriers of decentralization to
rural clinics related to ‘supply chain management, reagent
storage and calibration’ (Boehme et al. 2011). Unless
resources are decentralized to every dispensary, transport
systems that tie diagnostics to point of care will continue to
be needed. Clear-eyed programme analysis and a practical
operational plan that unites available services and estab-
lishes monitoring programmes does not require large
investments and can improve results as seen in our
programme.
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